Collaboration, Licensing and Other Arrangements - Revenue Allocation (Detail) - USD ($) $ in Millions			12 Months Ended
		Oct. 16, 2021	Dec. 31, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total transaction price			$ 50.9
R&D Services and License | Over Time
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total transaction price	[1]		$ 18.4
Progress Measure			Ratably
Recognition Period	[2]		May 2021 - Oct 2021
Pre-Commercial Services | Over Time
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total transaction price	[1]		$ 4.6
Progress Measure			Input
Recognition Period	[3]		% of completion of costs
Next-Gen R&D Services | Over Time
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total transaction price	[1]		$ 7.2
Progress Measure			Input
Recognition Period	[3]		% of completion of costs
Facility Expansion Services | Point In Time
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total transaction price	[1],[4]		$ 20.7
Recognition Period	[4],[5]		Transfer of control
Collaboration and License Agreement | United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total transaction price			$ 50.9
Collaboration and License Agreement | R&D Services and License | United Therapeutics Corporation | Over Time
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Progress Measure	[6]	Ratably
Recognition Period	[6],[7]	Aug 2021 - Oct 2021
Collaboration and License Agreement | Next-Gen R&D Services | United Therapeutics Corporation | Over Time
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total transaction price	[1],[8]	$ 4.8
Progress Measure	[8]	Input
Recognition Period	[8],[9]	% of completion of costs
Clinical Supplies | Collaboration and License Agreement | United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total transaction price			105.8
Clinical Supplies | Collaboration and License Agreement | R&D Services and License | United Therapeutics Corporation | Over Time
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total transaction price			$ 105.8
Allocation of Price			100.00%
Progress Measure			Ratably
Recognition Period	[10]		Sep 2018 - Dec 2021

[1] Allocation is based on management’s assessment of the stand-alone selling price of each performance obligation.

[2] Represents the estimated period when the R&D Services performance obligation will be substantially complete.

[3] Pre-Commercial Services and Next-Gen R&D Services performance obligations will be satisfied over time using the input method based on the costs incurred to date as a percentage of the total estimated costs to fulfill the contract. Incurred cost represents work performed, which corresponds with, and thereby best depicts, the transfer of control to the customer.

[4] The Company also acts as agent for the procurement of equipment for the manufacturing expansion for the UT Equipment. The Company received $5.0 million from UT for the UT Equipment, which was recognized as deposits from customer on the consolidated balance sheet and will be released as the title is transferred to UT.

[5] The Facility Expansion Services performance obligation would be recognized as control of manufactured products is transferred to the customer.

[6] The license for the Company’s IP was considered to be interdependent with the development activities to support approval of Tyvaso DPI. A sales-based royalty is promised in exchange for the IP license; therefore, the royalties associated with the license are excluded from the determination of the transaction price and the Company will recognize revenue as the sale of Tyvaso DPI to a patient occurs.

[7] Represents the period when the revenue for the R&D Services performance obligation was recognized.

[8] The standalone selling price (“SSP”) for the Next-Gen R&D Services performance obligation was based on industry ratios as well as the Company’s historical R&D projects. The transaction price for the Next-Gen R&D Services was based on fixed consideration which was allocated between performance obligations as discussed in note (2) above.

[9] The Next-Gen R&D Services performance obligation will be satisfied over time using the input method based on the costs incurred to date as a percentage of the total estimated costs to fulfill the contract. Incurred cost represents work performed, which corresponds with, and thereby best depicts, the transfer of control to the customer.

[10] Recognition period represents the estimated period to satisfy the performance obligation.